B. Riley Expects Stronger Earnings for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at B. Riley lifted their FY2024 earnings estimates for shares of X4 Pharmaceuticals in a report released on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of ($0.17) for the year, up from their prior estimate of ($0.68). The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.67) per share. B. Riley also issued estimates for X4 Pharmaceuticals' FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.16) EPS.

A number of other equities analysts have also weighed in on the stock. HC Wainwright cut their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Stifel Nicolaus dropped their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 12.4 %

NASDAQ XFOR traded down $0.05 on Wednesday, hitting $0.32. 1,328,932 shares of the company were exchanged, compared to its average volume of 2,361,571. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The company has a market cap of $54.99 million, a PE ratio of -4.09 and a beta of 0.39. The stock has a fifty day moving average of $0.57 and a 200-day moving average of $0.73. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the business. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals during the 3rd quarter worth $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth about $37,000. Price T Rowe Associates Inc. MD increased its holdings in shares of X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company's stock valued at $55,000 after acquiring an additional 12,514 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of X4 Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Finally, Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company's stock worth $109,000 after buying an additional 23,831 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 239,436 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares in the company, valued at approximately $581,742.15. The trade was a 18.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. Insiders sold 580,800 shares of company stock worth $321,447 over the last 90 days. Company insiders own 1.62% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.